Duration of Antibiotics in Infective Exacerbations of Cystic Fibrosis

• Status: Unknown status
• Trial end date: 2011-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Cystic Fibrosis patients attending with infective exacerbations will be enrolled into the study. The trial is a double blinded, randomised trial with patients randomised to 10,14 or 21 days of antibiotic therapy, comprising of tobramycin and either ceftazidime or meropenem.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Imperial College London
• Treatments: Anti-Bacterial Agents; Ceftazidime; Meropenem; Tobramycin

Criteria

Inclusion Criteria:

• 16 years or older

• Diagnosis of Cystic Fibrosis

• Presenting with Infective exacerbation

Exclusion Criteria:

• Unable to give consent

• Allergy to study medications

• Intolerance of aminoglycoside antibiotics

• Pseudomonas resistant to study antibiotics

• On the active transplant list or FEV1<20% predicted

• Pregnancy/breast-feeding

• Co-existent ABPA requiring a change in treatment

• Co-existent mycobacterial infection

• A previous participant in the study